NLRP3 inflammasome activation has also been documented in vivo in the transgenic APP/PS1 mouse model of AD, and deficiency in NLRP3 significantly ameliorated spatial memory deficits and hyperactive behavior in these mice, which was associated with reduced hippocampal and cortical Aβ deposition, smaller plaque volumes, decreased levels of pro‐inflammatory cytokines, and improved microglial phagocytic ability (Heneka et al, 2013). This evidence concerns the gene APP and Alzheimer disease.